Organization
Atea Pharmaceuticals
14 clinical trials
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of AT-752 in Patients With Dengue InfectionStatus: Terminated, Estimated PCD: 2023-01-19
Clinical trial
A Phase 1, Open-Label Study to Assess Comparative Bioavailability and Effect of Food on a Prototype Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir Versus Individual Dosage Forms Taken Concomitantly in Healthy Adult SubjectsStatus: Recruiting, Estimated PCD: 2024-02-12
Clinical trial
A Phase 1, Open-Label, Parallel-Group, Single-Dose Adaptive Study to Evaluate the Safety and Pharmacokinetics of AT-527 in Adult Subjects With Normal and Impaired Renal Function Sub-Study: Effects of Probenecid on the Pharmacokinetics of AT-527 in Healthy Adult SubjectsStatus: Recruiting, Estimated PCD: 2024-04-23
Clinical trial
A Phase 2, Open-label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic Hepatitis C Virus (HCV) InfectionStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1, Multicenter, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Bemnifosbuvir (AT-527) in Adult Subjects With Normal and Impaired Hepatic FunctionStatus: Recruiting, Estimated PCD: 2024-03-29
Clinical trial
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Drug-Drug Interaction Potential Between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy®) in Healthy Adult SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-05-30
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A First-in Human, Randomized, Double-blind, Placebo Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AT-752 in Healthy SubjectsStatus: Completed, Estimated PCD: 2021-11-14
Clinical trial
A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Assess the Antiviral Activity and Safety of AT-752 in a Dengue Human Challenge ModelStatus: Terminated, Estimated PCD: 2023-03-16
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects With Moderate COVID-19Status: Terminated, Estimated PCD: 2022-01-10
Clinical trial
A Phase 1, Open-Label Study to Evaluate the Potential Drug-Drug Interaction Between Bemnifosbuvir and Ruzasvir and Food-Drug Interaction in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2023-03-15
Clinical trial
A Phase 1, Double-blind, Single-dose, Randomized, Placebo and Active-Controlled, Four-Way Crossover Study Evaluating the Effects of Bemnifosbuvir on Cardiac Repolarization in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2023-05-31
Clinical trial
Phase 1, Multiple Dose, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AT-527 Following Oral Administration Under Fasting Conditions or With a Meal in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2022-08-23
Clinical trial
A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Bemnifosbuvir in Healthy Adult Japanese SubjectsStatus: Completed, Estimated PCD: 2023-05-19